Topical finasteride is a version of the well-known hair loss drug that you apply to the scalp instead of swallowing. The idea is simple: treat the scalp directly and keep less of the drug in the rest of the body. The evidence for that idea is promising but limited, and the regulatory picture in the United States is more complicated than many product pages suggest. This guide covers what trials have found for hair loss, how it compares with oral finasteride and minoxidil, and what the FDA has said about it.
What topical finasteride is
Topical finasteride is finasteride applied to the scalp as a spray, solution or gel instead of taken as a tablet, used as a hair loss treatment for pattern hair loss. Finasteride treats androgenetic alopecia by reducing DHT, a hormone that acts on hair follicles. As a topical medication, this topical formulation is meant to treat the scalp directly. Many products pair it with minoxidil. In the US, these are typically compounded by pharmacies, with minoxidil compounded alongside finasteride, and are usually prescribed through telehealth services. It is a topical treatment, not a hair transplant (see our hair transplant vs non-surgical guide).
Is topical finasteride FDA approved?
No. There is no FDA-approved topical finasteride. Compounded topical versions do not have FDA-approved labeling. The FDA issued an alert on the subject in April 2025.
The agency reviewed 32 adverse event cases reported to the FDA Adverse Event Reporting System between 2019 and 2024. The reported effects resembled those linked to oral finasteride and included erectile dysfunction, anxiety, depression and insomnia. Most reports said the effects continued after the product was stopped. The FDA also said that absorption through the skin into the bloodstream is expected, so finasteride may reach the rest of the body.
The FDA's 2025 compliance annual report adds that consumers reported being unaware of the potential adverse events. News coverage of the alert also listed brain fog, fatigue, decreased libido, testicular pain and suicidal ideation among reported symptoms. The alert followed a Wall Street Journal report on men who had side effects after buying from Hims and Keeps. Both companies said they disclose risks on their websites and packaging.
Outside the US, one search summary suggested that standardized topical sprays have been authorized in several European countries since 2020. We could not verify the countries or the product, so treat that as unconfirmed.
Does topical finasteride work for hair loss?
The strongest evidence is a Phase III randomized, controlled clinical trial of a topical finasteride spray solution for hair loss in male androgenetic alopecia (Piraccini et al., 2022). It compared a 0.25% finasteride spray with placebo and with oral finasteride 1 mg over 24 weeks (see our why am i losing hair guide).
- The spray significantly improved hair count compared with placebo.
- The hair regrowth was similar to the oral tablet: reported gains were 20.2 hairs/cm² for the spray and 21.1 hairs/cm² for the tablet.
- Systemic exposure was markedly lower, with less effect on serum DHT.
A 2018 systematic review in the Journal of Drugs in Dermatology included seven articles. Every study showed reduced hair loss and higher total and terminal hair counts. Scalp and plasma DHT fell, and serum testosterone did not change. The authors called the evidence for this hair loss approach limited but promising. An older study of a 1% finasteride gel (Hajheydari, 2009) reportedly found that both the gel and a 1 mg oral tablet significantly increased hair counts over six months, though we only saw a summary of that paper.
The main caveat is duration. The randomized Phase III evidence centers on about 24 weeks, and long-term head-to-head data against men using oral finasteride remain limited. (For a related topic, see our minoxidil shedding page.)
Topical finasteride compared with oral finasteride
On hair growth, the best trial found that finasteride works about as well as a topical spray as it does as a tablet. The difference is meant to be in exposure. In the Phase III trial, the spray produced markedly lower systemic exposure than the oral tablet, one of the oral medications used for pattern hair loss. That is the reasoning behind hoping for fewer side effects elsewhere in the body.
Be careful with specific numbers. Consumer sites quote different figures for how much each form lowers serum DHT. One gives about 72% for oral and 25% for topical, while others give 55.6% and 34.5%. We could not reconcile these against primary papers, so we do not quote a percentage here.
Be careful with safety claims too. Some consumer sites describe a topical solution as causing almost no side effects beyond the scalp, mostly local irritation. The FDA says skin absorption is expected and that adverse events resemble those of oral finasteride. The FDA's position carries more weight than a company's marketing.
Topical finasteride and minoxidil together
Minoxidil is a separate hair growth medication, sold as a minoxidil solution, and many products pair it with finasteride (see our finasteride vs minoxidil guide). A 2025 meta-analysis pooled seven randomized trials with 396 participants comparing topical minoxidil plus finasteride with minoxidil alone. Hair density rose by a mean difference of 9.22 and hair diameter, a measure of hair thickness and a sign of thicker hair, by 2.26. The authors rated the main outcomes as moderate-certainty evidence and noted heterogeneity and small samples.
This shows that adding finasteride helps beyond minoxidil alone. It is not evidence about finasteride used on its own.
Real-world use of compounded products
A January 2026 retrospective analysis in JMIR Dermatology covered 638,629 men with androgenetic alopecia, a common cause of hair loss, who received a compounded finasteride and minoxidil product between April 2021 and April 2025. As of June 2025, three such products were available through Hims & Hers. The first author is affiliated with Hims & Hers, whose platform data were analyzed, so read it with that conflict of interest in mind. Quality may also vary between compounding pharmacies.
Side effects and risks to others
- Whole-body effects: The FDA reports effects similar to oral finasteride, including sexual, mood and sleep symptoms, often persisting after stopping.
- Exposure of others: The FDA warned of risk through handling or transfer of the product, especially to women. Finasteride can cause birth defects in male babies.
- Unknown strength: Compounded strengths vary, and we found no regulator or guideline dosing advice. The Phase III spray was 0.25% w/w.
What we could not confirm
We did not find a professional-society guideline position on hair loss care, firm advice on use by women, or pricing. The trials we reviewed measured hair count and density, so we cannot promise longer hair. Xyon is a brand that appears in searches for this topic, but we did not review it, so we cannot say how Xyon works or describe the Xyon platform. Topical finasteride is also not currently a listed treatment category on this site, so we cannot say which clinics offer it. See our non-surgical hair loss treatment page for related hair loss treatments, and ask a clinician for personal advice.
Frequently Asked Questions
Is topical finasteride FDA approved?
No. There is no FDA-approved topical finasteride, and compounded products do not carry FDA-approved labeling.
Is topical finasteride as effective as oral finasteride?
In a 24-week Phase III trial, a 0.25% spray gave similar hair-count gains to the oral tablet. Long-term comparison data are limited.
Does topical finasteride avoid systemic side effects?
Not entirely. Trials found lower exposure in the body, but the FDA says skin absorption is expected and has reviewed adverse event reports similar to those of oral finasteride.
Does adding minoxidil help?
A 2025 meta-analysis found that topical minoxidil plus finasteride improved hair measures more than minoxidil alone.
Can others be affected by topical finasteride?
The FDA warned of risk through handling or transfer, especially to women, because finasteride can cause birth defects in male babies.